Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 101 from EUR 104 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q3 results following a check-in with IR. The firm also notes there has been increasing interest from investors on the possibility of a Dupixent settlement that could extend the product loss of exclusivity beyond the assumed current expiration in the wake of a series of recent patent settlements.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Novavax’s Nuvaxovid EU approval triggers $25M milestone payment from Sanofi
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Revvity announces program to expand type 1 diabetes offering
- Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz